Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome
Condition(s) studied
Investigational drug(s) / intervention(s)
Intravesical Ozone Therapy: Patients received 50 mL ozonated saline (20-40 µg/mL) intravesically twice weekly for 3 weeks.
Placebo (Normal Saline): Patients received 50 mL normal saline intravesically twice weekly for 3 weeks.
Control: Patients continued standard care (e.g., oral pentosan polysulfate) without intravesical intervention.
Study summary
This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.
Eligibility
Primary outcome measure(s)
- Change in O'Leary-Sant ICSI Score — Baseline to Week 3
Reduction in symptom severity measured by the O'Leary-Sant Interstitial Cystitis Symptom Index (range 0-19).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| İstanbul Başakşehir Çam Ve Sakura Şehir Hastanesi | Istanbul | Turkey (Türkiye) |
More Medipol University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06863220 on ClinicalTrials.gov ↗ ← All trials in Turkey